Clinical Trial Update: MLN8237 for a Subject With Adenocarcinoma of the Prostate

View source ↗

Summary

Clinical trial update indicates that MLN8237 (alisertib) for prostate cancer is no longer available. The update does not present new efficacy or safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• MLN8237 (alisertib)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Prostate Cancer | Status: NO_LONGER_AVAILABLE